Muscle Mitochondrial Pyruvate Carrier Disruption Alters Amino Acid Metabolism to Maintain Muscle Mass During Recovery from Obesity
Muscle Mitochondrial Pyruvate Carrier Disruption Alters Amino Acid Metabolism to Maintain Muscle Mass During Recovery from Obesity
批准号:
10618365
负责人:
Jane Buchanan
金额:
$3.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-06-08 至 2024-05-07
关键词:
AccelerationAcidsAcuteAddressAffectAgeAlanineAmino AcidsAnabolismAspartateBody CompositionBody WeightBody Weight decreasedBranched-Chain Amino AcidsCell Culture TechniquesChronicCitric Acid CycleDataDiabetes MellitusDietDisease OutcomeExcretory functionFatty acid glycerol estersFellowshipGenerationsGeneticGlucoseGlycolysisGoalsHealthHyperglycemiaInsulinInsulin ResistanceInterventionKnock-outKnowledgeLabelLinkLiverMaintenanceMeasurementMetabolicMetabolic DiseasesMetabolismMissionMitochondriaModelingMusMuscleMuscle FibersMuscle MitochondriaMuscle ProteinsMuscular AtrophyNitrogenNon-Insulin-Dependent Diabetes MellitusObesityOrganOutcomePathogenesisPatientsPhysiciansProductionProtein BiosynthesisProteinsPublic HealthPublishingPuromycinPyruvatePyruvate Metabolism PathwayRecoveryResearchRisk FactorsScientistSkeletal MuscleTestingThinnessTissuesTrainingTransfer RNA AminoacylationUnited States National Institutes of HealthWeightWild Type MouseWorkamino acid metabolismcareerdiabetes pathogenesisexperimental studyglucose disposalglucose uptakehepatic gluconeogenesisimprovedinsulin sensitivitymuscle formnitrogen balancenovelobesity treatmentoxidationpolypeptidepreservationpreventpyruvate carriersarcopeniaskeletal muscle metabolismskeletal muscle wastingstable isotopeuptake
中文摘要
项目总结/文摘
英文摘要
Project Summary/Abstract
Type 2 diabetes (T2D) is a widespread metabolic disorder that is characterized by insulin resistance
and hyperglycemia. Obesity, the excess accumulation of fat mass, is a major T2D risk factor and is strongly
associated with insulin resistance in skeletal muscle and liver, resulting in less glucose uptake by both organs.
Reduced muscle glucose uptake contributes to chronic hyperglycemia and is further exacerbated by excessive
hepatic gluconeogenesis. Because skeletal muscle is the largest tissue depot available for glucose disposal,
sarcopenia, the loss of skeletal muscle mass, also contributes to hyperglycemia. Though obesity and
sarcopenia are key factors that contribute to the pathogenesis of T2D, current therapies address insulin
availability or sensitivity without addressing the underlying imbalance between fat and muscle mass.
Disruption of the skeletal muscle mitochondrial pyruvate carrier (MPC) increases insulin sensitivity and
accelerates fat loss with complete muscle mass sparing in mice recovering from obesity. Thus, modulating
skeletal muscle pyruvate metabolism may be useful for treating altered body composition as a T2D root cause.
Our previous work has focused on understanding how muscle-specific MPC disruption increases fat oxidation.
However, how skeletal muscle MPC disruption maintains lean mass during fat mass loss is still not understood.
Therefore, the overall goal of this proposal is to understand how disrupting skeletal muscle mitochondrial
pyruvate uptake spares muscle mass during recovery from obesity. Based on our preliminary data, the central
hypothesis of this proposal is that muscle MPC disruption leads to muscle mass sparing during recovery from
obesity through: 1) a whole-body mechanism of altered substrate exchange between muscle and liver that
spares nitrogen for muscle mass; and 2) a unique, MPC disruption-dependent, muscle-autonomous
mechanism of nitrogen retention. Experiments for specific aim 1 will test the hypothesis that muscle MPC
disruption increases Cori Cycling, the exchange of lactate and glucose between muscle and liver, which spares
nitrogen for skeletal muscle protein and amino acid synthesis during weight loss and recovery from obesity.
Experiments for specific aim 2 will test the hypothesis that skeletal muscle MPC disruption increases aspartate
and branched-chain amino acid (BCAA) availability that leads to maintenance of myocellular protein content.
This research is significant because completion will provide mechanistic information on a way to alter skeletal
muscle metabolism that may inform treatment of obesity and sarcopenia contributing to T2D. This research is
novel because it addresses new concepts in cellular and systemic nitrogen handling.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Muscle Mitochondrial Pyruvate Carrier Disruption Alters Amino Acid Metabolism to Maintain Muscle Mass During Recovery from Obesity
-
批准号:10314711
-
项目类别:
-
资助金额:$3.67万
-
财政年份:2021
-
负责人:Jane Buchanan
-
依托单位:
Muscle Mitochondrial Pyruvate Carrier Disruption Alters Amino Acid Metabolism to Maintain Muscle Mass During Recovery from Obesity
-
批准号:10468660
-
项目类别:
-
资助金额:$3.74万
-
财政年份:2021
-
负责人:Jane Buchanan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: